Log in

NASDAQ:AGEN - Agenus Stock Price, Forecast & News

$2.35
-0.09 (-3.69 %)
(As of 03/27/2020 04:00 PM ET)
Today's Range
$2.30
Now: $2.35
$2.48
50-Day Range
$1.92
MA: $2.90
$4.39
52-Week Range
$1.82
Now: $2.35
$4.57
Volume1.75 million shs
Average Volume3.54 million shs
Market Capitalization$379.74 million
P/E RatioN/A
Dividend YieldN/A
Beta2.55
Agenus Inc., a clinical-stage immuno-oncology company, focuses on the discovery and development of therapies that engage the body's immune system to fight cancer. The company offers Retrocyte Display, an antibody discovery platform for the identification of fully-human and humanized monoclonal antibodies; SECANT yeast display, an antibody discovery platform used for the generation of novel monoclonal antibodies; and phage display technologies. It is also developing checkpoint modulating antibody candidates targeting GITR, OX40, TIM-3, LAG-3, and others. In addition, the company develops vaccine programs, including Prophage vaccine candidate; AutoSynVax, a synthetic neoantigen; and PhosPhoSynVax, a vaccine candidate designed to induce immunity against a class of tumor specific neoepitopes. Further, it develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. Additionally, the company engages in the development of CTLA-4 and PD-1 antagonists; and anti-CTLA-4, CD137, and TIGIT antibodies, as well as various multi-specific antibodies that are under various stages of development. Agenus Inc. has collaboration agreements with Incyte Corporation, Merck Sharpe & Dohme, and Recepta Biopharma SA.; and collaboration with Gilead Sciences, Inc. to develop immuno-oncology therapies. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.
Read More
Agenus logo

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:AGEN
CUSIP00847G70
Phone781-674-4400

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$150.05 million
Book Value($1.68) per share

Profitability

Net Income$-107,660,000.00

Miscellaneous

Employees294
Market Cap$379.74 million
Next Earnings Date5/8/2020 (Estimated)
OptionableOptionable

Receive AGEN News and Ratings via Email

Sign-up to receive the latest news and ratings for AGEN and its competitors with MarketBeat's FREE daily newsletter.


Agenus (NASDAQ:AGEN) Frequently Asked Questions

How has Agenus' stock been impacted by COVID-19 (Coronavirus)?

Agenus' stock was trading at $2.72 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, AGEN stock has decreased by 13.6% and is now trading at $2.35. View which stocks have been mosted impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Agenus?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Agenus in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Agenus.

When is Agenus' next earnings date?

Agenus is scheduled to release its next quarterly earnings announcement on Friday, May 8th 2020. View our earnings forecast for Agenus.

How were Agenus' earnings last quarter?

Agenus Inc (NASDAQ:AGEN) issued its earnings results on Thursday, March, 12th. The biotechnology company reported ($0.22) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.38) by $0.16. The biotechnology company had revenue of $34.50 million for the quarter, compared to the consensus estimate of $17.05 million. View Agenus' earnings history.

What price target have analysts set for AGEN?

1 equities research analysts have issued 12-month price objectives for Agenus' stock. Their forecasts range from $6.00 to $6.00. On average, they expect Agenus' share price to reach $6.00 in the next year. This suggests a possible upside of 155.3% from the stock's current price. View analysts' price targets for Agenus.

Has Agenus been receiving favorable news coverage?

News articles about AGEN stock have been trending very negative on Saturday, InfoTrie Sentiment reports. The research firm identifies negative and positive news coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Agenus earned a news impact score of -3.0 on InfoTrie's scale. They also gave headlines about the biotechnology company a news buzz of 4.0 out of 10, meaning that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the near future. View the latest news aboutAgenus.

Are investors shorting Agenus?

Agenus saw a increase in short interest in the month of February. As of February 28th, there was short interest totaling 13,020,000 shares, an increase of 7.2% from the February 13th total of 12,150,000 shares. Based on an average daily trading volume, of 1,720,000 shares, the short-interest ratio is presently 7.6 days. Currently, 12.4% of the company's shares are short sold. View Agenus' Current Options Chain.

Who are some of Agenus' key competitors?

What other stocks do shareholders of Agenus own?

Who are Agenus' key executives?

Agenus' management team includes the following people:
  • Dr. Garo H. Armen, Founder, Exec. Chairman & CEO (Age 66)
  • Dr. Jennifer Buell, Chief Operating Officer
  • Dr. Alexander R. Duncan, CTO & Head of Research (Age 57)
  • Dr. Christian Cortis, Chief Strategy Officer & Head of Fin. (Age 51)
  • Ms. Christine M. Klaskin, Principal Accounting Officer & VP of Fin. (Age 53)

What is Agenus' stock symbol?

Agenus trades on the NASDAQ under the ticker symbol "AGEN."

Who are Agenus' major shareholders?

Agenus' stock is owned by a variety of institutional and retail investors. Top institutional investors include State Street Corp (2.86%), Oracle Investment Management Inc. (2.02%), Geode Capital Management LLC (1.10%), Panagora Asset Management Inc. (0.69%), Charles Schwab Investment Management Inc. (0.52%) and Bank of New York Mellon Corp (0.34%). View institutional ownership trends for Agenus.

Which major investors are selling Agenus stock?

AGEN stock was sold by a variety of institutional investors in the last quarter, including Oxford Asset Management LLP, Chicago Equity Partners LLC, Bank of America Corp DE, Charles Schwab Investment Management Inc., Strs Ohio, New York State Common Retirement Fund, Zurcher Kantonalbank Zurich Cantonalbank, and Bank of New York Mellon Corp. View insider buying and selling activity for Agenus.

Which major investors are buying Agenus stock?

AGEN stock was acquired by a variety of institutional investors in the last quarter, including State Street Corp, Oracle Investment Management Inc., Captrust Financial Advisors, Renaissance Technologies LLC, Connor Clark & Lunn Investment Management Ltd., Connor Clark & Lunn Investment Management Ltd., Acadian Asset Management LLC, and Hussman Strategic Advisors Inc.. View insider buying and selling activity for Agenus.

How do I buy shares of Agenus?

Shares of AGEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Agenus' stock price today?

One share of AGEN stock can currently be purchased for approximately $2.35.

How big of a company is Agenus?

Agenus has a market capitalization of $379.74 million and generates $150.05 million in revenue each year. The biotechnology company earns $-107,660,000.00 in net income (profit) each year or ($0.80) on an earnings per share basis. Agenus employs 294 workers across the globe. View additional information about Agenus.

What is Agenus' official website?

The official website for Agenus is http://agenusbio.com/.

How can I contact Agenus?

Agenus' mailing address is 3 FORBES ROAD, LEXINGTON MA, 02421. The biotechnology company can be reached via phone at 781-674-4400 or via email at [email protected]


MarketBeat Community Rating for Agenus (NASDAQ AGEN)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  423 (Vote Outperform)
Underperform Votes:  332 (Vote Underperform)
Total Votes:  755
MarketBeat's community ratings are surveys of what our community members think about Agenus and other stocks. Vote "Outperform" if you believe AGEN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AGEN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/28/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel